Please login to the form below

Not currently logged in
Email:
Password:

lonafarnib

This page shows the latest lonafarnib news and features for those working in and with pharma, biotech and healthcare.

Deals in development

It doubled its phase III anticancer portfolio, with Novacea's high-dose capsule formulation of calcitriol, DN-101 (Asentar), joining its farnesyl protein transferase inhibitor lonafarnib (Sarasar) at the market end

Latest news

More from news
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 1 fully matching, plus 0 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Oncosec

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....